Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
Price : $35 *
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms OptiPOM
- 24 Jan 2019 Last checked against ClinicalTrials.gov record.
- 06 Aug 2018 Status changed from not yet recruiting to recruiting.
- 14 May 2018 New trial record